Contact
searchSearch
HMP Global
Login

Waldenström Macroglobulinemia Specialty Channel

News
Cyclophosphamide and Rituximab With Bortezomib Highly Effective for Patients With Treatment-Naive Waldenström Macroglobulinemia
04/01/2024

Jordan Kadish

Jordan Kadish
Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.
Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.
Cyclophosphamide and rituximab...
04/01/2024
Oncology
Quiz
Efficacy of Sequential Treatment Escalation Among Patients With Waldenström Macroglobulinemia
02/26/2024
02/26/2024
Oncology
News
Sequential Treatment Escalation May Extend Survival for Patients With Waldenström Macroglobulinemia
02/14/2024
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation...
02/14/2024
Oncology
Quiz
Comparing Outcomes of Zanubrutinib Versus Ibrutinib for Waldenström Macroglobulinemia
02/02/2024
True or False: Findings from a final analysis of the phase 3 ASPEN trial indicated that zanubrutinib exhibited similar efficacy and improved safety and tolerability compared to ibrutinib among patients with Waldenström macroglobulinemia,...
True or False: Findings from a final analysis of the phase 3 ASPEN trial indicated that zanubrutinib exhibited similar efficacy and improved safety and tolerability compared to ibrutinib among patients with Waldenström macroglobulinemia,...
True or False: Findings from a...
02/02/2024
Oncology
Quiz
B-DRC Combination Treatment for Waldenström Macroglobulinemia
05/30/2023
According to findings from a trial assessing the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide (B-DRC) as a first-line combination treatment for Waldenström macroglobulinemia, the median time to first response was ___ in...
According to findings from a trial assessing the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide (B-DRC) as a first-line combination treatment for Waldenström macroglobulinemia, the median time to first response was ___ in...
According to findings from a...
05/30/2023
Oncology
News
B-DRC Combination Treatment Yielded High Response Rates Among Patients With Waldenström Macroglobulinemia
04/19/2023
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the...
04/19/2023
Oncology
Quiz
Quiz: Zanubrutinib Versus Ibrutinib for Waldenström Macroglobulinemia
03/21/2023
True or False: According to findings of the phase 3 ASPEN trial, zanubrutinib yielded higher complete response rates and advantages in long-term safety versus ibrutinib among patients with Waldenström macroglobulinemia.
True or False: According to findings of the phase 3 ASPEN trial, zanubrutinib yielded higher complete response rates and advantages in long-term safety versus ibrutinib among patients with Waldenström macroglobulinemia.
True or False: According to...
03/21/2023
Oncology
News
Venetoclax Safe, Effective in Previously Treated Patients With Waldenström Macroglobulinemia
06/26/2022
Study findings suggest venetoclax is safe and effective in previously treated patients with WM, including those previously exposed to BTK inhibitors.
Study findings suggest venetoclax is safe and effective in previously treated patients with WM, including those previously exposed to BTK inhibitors.
Study findings suggest...
06/26/2022
Oncology
News
Ibrutinib Plus Rituximab for Waldenström Macroglobulinemia: Final Results From the iNNOVATE Trial
05/13/2022
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab...
05/13/2022
Oncology
News
Zanubrutinib Well Tolerated, Exhibits Consistent Safety Profile in Patients With B-Cell Malignancies
04/07/2022
According to a pooled analysis of data, zanubrutinib monotherapy for patients with B-cell malignancies is consistent with the toxicity profile of BTK inhibitors.
According to a pooled analysis of data, zanubrutinib monotherapy for patients with B-cell malignancies is consistent with the toxicity profile of BTK inhibitors.
According to a pooled analysis...
04/07/2022
Oncology
Computer
Quiz
Quiz: Does Ibrutinib Induce Durable Responses in Patients With WM?
04/05/2022
True or false: A phase 2 trial found that ibrutinib monotherapy induces high rates of durable responses in patients with WM.
True or false: A phase 2 trial found that ibrutinib monotherapy induces high rates of durable responses in patients with WM.
True or false: A phase 2 trial...
04/05/2022
Oncology

News

News
Cyclophosphamide and Rituximab With Bortezomib Highly Effective for Patients With Treatment-Naive Waldenström Macroglobulinemia
04/01/2024

Jordan Kadish

Jordan Kadish
Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.
Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.
Cyclophosphamide and rituximab...
04/01/2024
Oncology
News
Sequential Treatment Escalation May Extend Survival for Patients With Waldenström Macroglobulinemia
02/14/2024
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation...
02/14/2024
Oncology
News
B-DRC Combination Treatment Yielded High Response Rates Among Patients With Waldenström Macroglobulinemia
04/19/2023
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the...
04/19/2023
Oncology
News
Venetoclax Safe, Effective in Previously Treated Patients With Waldenström Macroglobulinemia
06/26/2022
Study findings suggest venetoclax is safe and effective in previously treated patients with WM, including those previously exposed to BTK inhibitors.
Study findings suggest venetoclax is safe and effective in previously treated patients with WM, including those previously exposed to BTK inhibitors.
Study findings suggest...
06/26/2022
Oncology
News
Ibrutinib Plus Rituximab for Waldenström Macroglobulinemia: Final Results From the iNNOVATE Trial
05/13/2022
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab...
05/13/2022
Oncology
News
Zanubrutinib Well Tolerated, Exhibits Consistent Safety Profile in Patients With B-Cell Malignancies
04/07/2022
According to a pooled analysis of data, zanubrutinib monotherapy for patients with B-cell malignancies is consistent with the toxicity profile of BTK inhibitors.
According to a pooled analysis of data, zanubrutinib monotherapy for patients with B-cell malignancies is consistent with the toxicity profile of BTK inhibitors.
According to a pooled analysis...
04/07/2022
Oncology
News
Treatment of Patients With R/R WM With Ixazomib Appears Safe and Effective
03/30/2022
Treatment of patients with R/R WM with the oral proteasome inhibitor ixazomib combined with subcutaneous rituximab was associated with a median duration of response of 36 months.
Treatment of patients with R/R WM with the oral proteasome inhibitor ixazomib combined with subcutaneous rituximab was associated with a median duration of response of 36 months.
Treatment of patients with R/R...
03/30/2022
Oncology
News
No Statistically Significant Impact of CXCR4 Mutations on Efficacy of Ibrutinib in WM
03/21/2022
Ibrutinib is a standard-of-care first line therapy for patients with WM. However, long-term follow-up results from a phase 2 trial found that for patients with WM treated with ibrutinib monotherapy, none experienced a complete response.
Ibrutinib is a standard-of-care first line therapy for patients with WM. However, long-term follow-up results from a phase 2 trial found that for patients with WM treated with ibrutinib monotherapy, none experienced a complete response.
Ibrutinib is a standard-of-care...
03/21/2022
Oncology
News
MYD88 Mutation, Other Distinguishing Characteristics May Help Identify WM
03/08/2022
MYD88 mutation and increased IgM peak levels help to distinguish WM from other indolent B-cell malignancies. In the study, the MYD88 mutation was found in almost all WM cases.
MYD88 mutation and increased IgM peak levels help to distinguish WM from other indolent B-cell malignancies. In the study, the MYD88 mutation was found in almost all WM cases.
MYD88 mutation and increased IgM...
03/08/2022
Oncology
News
Post-Transplant Ibrutinib Associated With Longer Survival in Twice-Relapsed WM
03/01/2022
Almost half of post-relapse WM patients relapse again following auto-HCT, according to findings from a recent study.
Almost half of post-relapse WM patients relapse again following auto-HCT, according to findings from a recent study.
Almost half of post-relapse WM...
03/01/2022
Oncology

Interactive Features

Quiz
Efficacy of Sequential Treatment Escalation Among Patients With Waldenström Macroglobulinemia
02/26/2024
02/26/2024
Oncology
Quiz
Comparing Outcomes of Zanubrutinib Versus Ibrutinib for Waldenström Macroglobulinemia
02/02/2024
True or False: Findings from a final analysis of the phase 3 ASPEN trial indicated that zanubrutinib exhibited similar efficacy and improved safety and tolerability compared to ibrutinib among patients with Waldenström macroglobulinemia,...
True or False: Findings from a final analysis of the phase 3 ASPEN trial indicated that zanubrutinib exhibited similar efficacy and improved safety and tolerability compared to ibrutinib among patients with Waldenström macroglobulinemia,...
True or False: Findings from a...
02/02/2024
Oncology
Quiz
B-DRC Combination Treatment for Waldenström Macroglobulinemia
05/30/2023
According to findings from a trial assessing the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide (B-DRC) as a first-line combination treatment for Waldenström macroglobulinemia, the median time to first response was ___ in...
According to findings from a trial assessing the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide (B-DRC) as a first-line combination treatment for Waldenström macroglobulinemia, the median time to first response was ___ in...
According to findings from a...
05/30/2023
Oncology
Quiz
Quiz: Zanubrutinib Versus Ibrutinib for Waldenström Macroglobulinemia
03/21/2023
True or False: According to findings of the phase 3 ASPEN trial, zanubrutinib yielded higher complete response rates and advantages in long-term safety versus ibrutinib among patients with Waldenström macroglobulinemia.
True or False: According to findings of the phase 3 ASPEN trial, zanubrutinib yielded higher complete response rates and advantages in long-term safety versus ibrutinib among patients with Waldenström macroglobulinemia.
True or False: According to...
03/21/2023
Oncology
Computer
Quiz
Quiz: Does Ibrutinib Induce Durable Responses in Patients With WM?
04/05/2022
True or false: A phase 2 trial found that ibrutinib monotherapy induces high rates of durable responses in patients with WM.
True or false: A phase 2 trial found that ibrutinib monotherapy induces high rates of durable responses in patients with WM.
True or false: A phase 2 trial...
04/05/2022
Oncology
blood cell
Quiz
Quiz: What is Post-Transplant Ibrutinib Associated With in WM?
03/07/2022
True or false: The median post-relapse OS is longer in patients with WM who received ibrutinib following an auto-HCT.
True or false: The median post-relapse OS is longer in patients with WM who received ibrutinib following an auto-HCT.
True or false: The median...
03/07/2022
Oncology
blood cell
Test Your Knowledge
Quiz: Is the CXCR4 Mutation Associated With Worse PFS for Patients With WM?
02/25/2022
True or false: CXCR4 mutations are associated with a lower chance of major and deep responses, as well as worse PFS, in patients with WM treated with ibrutinib therapy.
True or false: CXCR4 mutations are associated with a lower chance of major and deep responses, as well as worse PFS, in patients with WM treated with ibrutinib therapy.
True or false: CXCR4 mutations...
02/25/2022
Oncology
stethoscope
Test Your Knowledge
Quiz: Did the iNNOVATE Study Confirm Ibrutinib Plus Rituximab Efficacy for WM?
02/03/2022
True or false: Results of the double-blind, randomized, phase 3 iNNOVATE study confirmed the sustained efficacy of ibrutinib plus rituximab in patients with WM.
True or false: Results of the double-blind, randomized, phase 3 iNNOVATE study confirmed the sustained efficacy of ibrutinib plus rituximab in patients with WM.
True or false: Results of the...
02/03/2022
Oncology
health care
Test Your Knowledge
Quiz: Are Advances in WM, LPL Associated With Rituximab?
02/03/2022
Fill in the blank: A population-based study on patients with WM and LPL found the 5-year relative survival (RS) rate significantly ______ over time with the introduction of rituximab in the early-mid 2000s.
Fill in the blank: A population-based study on patients with WM and LPL found the 5-year relative survival (RS) rate significantly ______ over time with the introduction of rituximab in the early-mid 2000s.
Fill in the blank: A...
02/03/2022
Oncology
medical
Test Your Knowledge
Quiz: What Therapy has Similar Outcomes to Bendamustine-Rituximab for WM?
01/31/2022
True or false: In contrast to prior studies, data from a real-world population-based analysis of frontline therapy found RCVP and BR had similar outcomes in patients with TN WM.
True or false: In contrast to prior studies, data from a real-world population-based analysis of frontline therapy found RCVP and BR had similar outcomes in patients with TN WM.
True or false: In contrast to...
01/31/2022
Oncology

Recent News

News
Cyclophosphamide and Rituximab With Bortezomib Highly Effective for Patients With Treatment-Naive Waldenström Macroglobulinemia
04/01/2024

Jordan Kadish

Jordan Kadish
Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.
Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.
Cyclophosphamide and rituximab...
04/01/2024
Oncology
News
Sequential Treatment Escalation May Extend Survival for Patients With Waldenström Macroglobulinemia
02/14/2024
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation...
02/14/2024
Oncology
News
B-DRC Combination Treatment Yielded High Response Rates Among Patients With Waldenström Macroglobulinemia
04/19/2023
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the...
04/19/2023
Oncology
News
Venetoclax Safe, Effective in Previously Treated Patients With Waldenström Macroglobulinemia
06/26/2022
Study findings suggest venetoclax is safe and effective in previously treated patients with WM, including those previously exposed to BTK inhibitors.
Study findings suggest venetoclax is safe and effective in previously treated patients with WM, including those previously exposed to BTK inhibitors.
Study findings suggest...
06/26/2022
Oncology
News
Ibrutinib Plus Rituximab for Waldenström Macroglobulinemia: Final Results From the iNNOVATE Trial
05/13/2022
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab...
05/13/2022
Oncology
News
Zanubrutinib Well Tolerated, Exhibits Consistent Safety Profile in Patients With B-Cell Malignancies
04/07/2022
According to a pooled analysis of data, zanubrutinib monotherapy for patients with B-cell malignancies is consistent with the toxicity profile of BTK inhibitors.
According to a pooled analysis of data, zanubrutinib monotherapy for patients with B-cell malignancies is consistent with the toxicity profile of BTK inhibitors.
According to a pooled analysis...
04/07/2022
Oncology
News
Treatment of Patients With R/R WM With Ixazomib Appears Safe and Effective
03/30/2022
Treatment of patients with R/R WM with the oral proteasome inhibitor ixazomib combined with subcutaneous rituximab was associated with a median duration of response of 36 months.
Treatment of patients with R/R WM with the oral proteasome inhibitor ixazomib combined with subcutaneous rituximab was associated with a median duration of response of 36 months.
Treatment of patients with R/R...
03/30/2022
Oncology
News
No Statistically Significant Impact of CXCR4 Mutations on Efficacy of Ibrutinib in WM
03/21/2022
Ibrutinib is a standard-of-care first line therapy for patients with WM. However, long-term follow-up results from a phase 2 trial found that for patients with WM treated with ibrutinib monotherapy, none experienced a complete response.
Ibrutinib is a standard-of-care first line therapy for patients with WM. However, long-term follow-up results from a phase 2 trial found that for patients with WM treated with ibrutinib monotherapy, none experienced a complete response.
Ibrutinib is a standard-of-care...
03/21/2022
Oncology
News
MYD88 Mutation, Other Distinguishing Characteristics May Help Identify WM
03/08/2022
MYD88 mutation and increased IgM peak levels help to distinguish WM from other indolent B-cell malignancies. In the study, the MYD88 mutation was found in almost all WM cases.
MYD88 mutation and increased IgM peak levels help to distinguish WM from other indolent B-cell malignancies. In the study, the MYD88 mutation was found in almost all WM cases.
MYD88 mutation and increased IgM...
03/08/2022
Oncology
News
Post-Transplant Ibrutinib Associated With Longer Survival in Twice-Relapsed WM
03/01/2022
Almost half of post-relapse WM patients relapse again following auto-HCT, according to findings from a recent study.
Almost half of post-relapse WM patients relapse again following auto-HCT, according to findings from a recent study.
Almost half of post-relapse WM...
03/01/2022
Oncology
News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
FDA Alerts
Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer
01/17/2025
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.
Based on results from the phase...
01/17/2025
Oncology
FDA Approval
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL
01/17/2025
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.
The FDA granted approval to...
01/17/2025
Oncology
News
Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL
01/16/2025
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.
Inferior survival outcomes are...
01/16/2025
Oncology
News
Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population
01/15/2025
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
Treatment with ciltacabtagene...
01/15/2025
Oncology
News
Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer
01/14/2025
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the...
01/14/2025
Oncology
News
First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
01/14/2025
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.
According to results from the...
01/14/2025
Oncology
News
Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma
01/08/2025
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.
Final results from the phase 3...
01/08/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer
01/06/2025
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...
Interim analysis results from...
01/06/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use